Laura Kelly, DAOM — Women’s Health Researcher & Clinician
Dr. Laura Kelly is a researcher and clinician examining several gaps in women's health that sit in plain sight: medicine recognizes androgen biology in female genital tissue, but has no standard androgen-based treatment framework; the external vulva is an anatomically distinct but often overlooked treatment target; and sexual drive, cognitive access to desire, and genital capacity may follow different trajectories across midlife.
She is a Research Scholar at the Ronin Institute and US Principal Investigator on Exploring the experiences, perceptions, meaning and coping strategies of menopausal women in the Global South and Global North: a comparative study, a 26-country study led from the University of Bern. She is a California-licensed primary care provider specializing in women's health and aging, and a member of the Endocrine Society and the International Society for the Study of Women's Sexual Health (ISSWSH).
Media inquiries: laura@drlaurakelly.com — subject line "Media." Response within 24 hours, Monday–Friday, Pacific time.
ORCID: 0000-0001-6586-7308
[Download high-resolution headshot]
Ideas Laura brings to the conversation
Androgen biology is established. External vulvar medicine has not translated it into standard care.
Human vulvar vestibular and vaginal tissues express androgen receptors and local steroid-metabolizing machinery. The biology is established.
Yet routine care for midlife genital symptoms remains centered on estrogen-based vaginal therapy, lubricants, moisturizers, and symptom management. There is no standard androgen-directed treatment pathway specifically for the external vulva.
That disconnect is one of Laura's central research questions:
If androgen signaling is part of normal genital-tissue biology, why is there no established clinical framework for supporting androgen-responsive external vulvar tissue?
This does not mean estrogen is unimportant, or that every woman needs androgen treatment. It means the biology is more complex than an estrogen-only framework suggests.
The vulva is not the vagina — and that matters for treatment.
Medicine routinely uses terms such as vulvovaginal atrophy and vaginal dryness to describe symptoms that may occur across several anatomically different structures.
But the vagina, vestibule, introitus, labia, and clitoral tissues are not interchangeable.
That distinction may be particularly important in sexual pain. The vestibule and vaginal opening are common sites of superficial penetrative pain, yet this experience is frequently described broadly as "vaginal pain" or "vaginal dryness."
Laura is interested in what happens when anatomically distinct tissues are treated conceptually as a single compartment — and whether this has contributed to the external vulva remaining an under-recognized treatment target.
Route of delivery may be an overlooked variable.
Most of the clinical evidence for local DHEA, and much of the evidence for local estrogen, concerns intravaginal administration.
That does not necessarily tell us what happens when a compound is applied directly to external vulvar tissue. Adjacent tissues can influence one another, but intravaginal exposure is not automatically equivalent to direct external vulvar exposure.
Laura's current research examines whether route of delivery deserves greater attention in vulvar medicine, including questions of local tissue exposure, systemic exposure, dose, and clinical effect.
The important point is not that one route has been proven superior. It is that the question has not been adequately answered.
"Libido" is several different biological problems hiding inside one word.
Laura's published Drive–Capacity Model separates two components of female sexual function that are often treated as though they are the same:
Drive — central sexual motivation, wanting, and mental arousal.
Capacity — the peripheral physiological ability of genital tissue to respond.
These systems can change on different timelines. A woman may therefore experience:
- "I want to want, but I don't."
- reduced spontaneous desire with preserved orgasmic capacity;
- genital responsiveness without much subjective arousal;
- desire that remains intact while pain or tissue change limits sexual activity.
Laura's current work extends this framework with a third dimension: Access — whether sexual motivation or arousal becomes cognitively available in a particular state. Stress, sleep disruption, attentional load, hormonal transition, and competing cognitive demands may influence access even when underlying sexual capacity remains intact.
Together, Drive, Capacity, and Access offer a more granular way of understanding female sexual change than the single label low libido.
Perimenopause may begin before the conventional treatment framework does.
A woman does not have to stop menstruating before genital and sexual symptoms can begin. Longitudinal and cross-sectional studies show increasing genital dryness and changes in sexual function during the menopausal transition itself.
That creates an important mismatch: women can begin experiencing symptoms before medicine typically introduces them to the concept of menopausal genital care.
Laura argues that vulvar health belongs in anticipatory perimenopause care, rather than appearing for the first time after menopause under the diagnosis of genitourinary syndrome of menopause.
Her shorthand for the idea is:
Vulvar care shouldn't begin at menopause.
About Laura Kelly
Laura Kelly is a clinician, researcher, author, and founder working at the intersection of women’s health, aging, sexual function, and personalized medicine.
Her clinical approach combines conventional laboratory assessment with systems biology, precision medicine, and, when clinically appropriate, metabolomic and advanced functional testing. This broader phenotyping informs her interest in why women with apparently similar menopausal states can experience very different changes in sexual function, metabolism, cognition, tissue health and aging.
Her research has increasingly focused on questions that emerge from clinical practice but are incompletely represented in conventional models of care: female sexual function across the menopausal transition, vulvar hormone biology, DHEA and intracrine signaling, anatomical distinctions within female genital tissue, route of local hormone delivery, and personalized risk.
This work led her to found The Vulva Company, a science-led company focused specifically on external vulvar health across hormonal transitions.
Her approach emphasizes a deliberate distinction among:
what the evidence establishes; what the existing biology makes plausible; and what still requires direct clinical study.
Professional affiliations
Research Scholar — Ronin Institute
Independent scholarly affiliation supporting interdisciplinary research.
Member — Endocrine Society
Professional scientific society focused on endocrine research, clinical endocrinology, and hormone science.
Member — International Society for the Study of Women’s Sexual Health (ISSWSH)
Multidisciplinary professional society focused on the science, diagnosis, and treatment of women’s sexual health.
Nationally board-certified — NCCAOM
National Certification Commission for national practice in the US.
Selected research
The Drive–Capacity Model: A Systems Biology Framework for Midlife Female Sexual Function
Kelly L. Research Connections. Oxford Academic. 2026;1(2):vmag023. doi:10.1093/rescon/vmag023
Read the article on Oxford Academic
The framework proposes that central sexual motivation and peripheral genital capacity can follow different trajectories across the menopausal transition. This separation offers a potential explanation for clinical experiences difficult to describe using the single construct of "libido," including diminished wanting despite preserved physiological sexual response.
Comparative study of menopause across the Global South and Global North (ongoing)
US Principal Investigator — Exploring the experiences, perceptions, meaning and coping strategies of menopausal women in the Global South and Global North: a comparative study. University of Bern. 26 countries.
A cross-national study of how menopause is experienced, understood, and managed across widely differing health systems and cultural contexts.
Frameworks in development
Two further frameworks are in progress. Their status is given explicitly so journalists can characterize them accurately.
Genitourinary Syndrome of Lactation (GSL) — manuscript under peer review
A proposed framework describing the distinct genital and urinary tissue changes of the postpartum lactational period, which are currently described using terminology developed for menopause despite differing in mechanism, time course, and reversibility.
Status: revised manuscript currently with reviewers. Not yet published; please characterize as proposed.
Estrogen-Withdrawal Executive Dysregulation (EWED) — in development
A proposed framework describing changes in executive function during estrogen withdrawal as a state-dependent phenomenon rather than a fixed cognitive deficit.
Status: in development, not yet submitted. Available for background discussion; not appropriate for citation as established.
Current research areas
- external vulvar hormone biology
- DHEA and intracrine signaling
- external versus intravaginal routes of hormone delivery
- perimenopausal and menopausal sexual function
- postpartum vulvar biology
- personalized hormone and health risk
- female skeletal aging and fracture risk
For her complete and current scholarly record, see her ORCID profile.
Books and edited volumes
The Implementation of Personalized Precision Medicine. Senior editor and contributor. Academic Press / Elsevier, 2024.
The Healthy Bones Nutrition Plan and Cookbook (2017) and The Healthy Bones Plant-Based Nutrition Plan and Cookbook (2024). Chelsea Green / Rizzoli.
Interview and commentary topics
1. What a 26-country study shows about menopause care How menopause is experienced, named, and treated across the Global South and Global North — and what the differences reveal about how much of "the menopause experience" is biology versus health system and culture.
2. Why vulvar care should begin at perimenopause Genital symptoms can begin while women are still menstruating. What the evidence shows about vulvar and sexual change during perimenopause — and why genital care still tends to begin after menopause.
3. The vulva is not the vagina Why anatomically distinct female genital tissues continue to be grouped together clinically, why the vestibule and introitus matter in superficial sexual pain, and whether greater anatomical precision could change treatment.
4. The androgen biology medicine rarely discusses Human genital tissues contain androgen receptors and local steroid-metabolizing machinery. Yet there is no established androgen-directed treatment pathway. Why has the biology advanced farther than the clinical model?
5. Does route matter? Most local hormone research studies intravaginal administration. What can — and cannot — be inferred about direct external vulvar treatment from that evidence?
6. Why "low libido" may be the wrong diagnosis How Drive, Capacity, and Access can diverge — and why "I want to want," reduced spontaneous desire, preserved orgasm, pain, and cognitive overload may represent very different biological problems.
7. Why vaginal treatment may not answer every external symptom How to think about location when women report continued burning, friction, introital discomfort, or external dryness despite systemic hormone therapy or vaginal treatment — and why persistent symptoms also require evaluation for nonhormonal causes.
8. Bone health, osteoporosis, and the menopause transition Why bone loss accelerates around menopause, what women can do before osteoporosis develops, and why fracture prevention requires more than calcium and a DXA score.
9. Precision approaches to skeletal aging How genetics, body composition, nutrition, metabolic health, muscle, medication exposure, and hormonal state can modify skeletal risk.
Quotable perspectives
“Androgen biology is established in female genital tissue. What medicine does not yet have is a standard androgen-directed treatment model for the vulva.”
“The vagina and vulva are adjacent. They are not the same anatomical treatment target.”
“If a woman’s pain is at the vaginal opening, calling the entire problem ‘vaginal dryness’ may hide the tissue we actually need to examine.”
“The unresolved question isn’t whether intravaginal treatment can affect nearby tissue. It can. The question is whether we should assume that route and direct external treatment are interchangeable.”
“Low libido is often treated as though it were one biological state. Drive, genital capacity, and cognitive access to desire can fail independently.”
“A woman can still be menstruating while her sexual function and genital comfort are already changing. Vulvar care shouldn’t begin at menopause.”
About Laura Kelly
Laura Kelly is a researcher, clinician, author, and founder working at the intersection of women's health, aging, sexual function, and personalized medicine.
Her research focuses on questions that emerge from clinical practice but are incompletely represented in conventional models of care: female sexual function across the menopausal transition, vulvar hormone biology, DHEA and intracrine signaling, anatomical distinctions within female genital tissue, route of local hormone delivery, and personalized risk.
Her clinical approach combines conventional laboratory assessment with systems biology, precision medicine, and, when clinically appropriate, metabolomic and advanced phenotyping. This informs her interest in why women with apparently similar menopausal states can experience very different changes in sexual function, metabolism, cognition, tissue health, and aging.
This work led her to found The Vulva Company, a science-led company focused on external vulvar health across hormonal transitions.
Her approach emphasizes a deliberate distinction among what the evidence establishes, what the existing biology makes plausible, and what still requires direct clinical study.
Affiliations and credentials
Research Scholar — Ronin Institute Independent scholarly affiliation supporting interdisciplinary research.
US Principal Investigator — University of Bern comparative menopause study Exploring the experiences, perceptions, meaning and coping strategies of menopausal women in the Global South and Global North: a comparative study.
Member — Endocrine Society
Member — International Society for the Study of Women's Sexual Health (ISSWSH)
Doctor of Acupuncture and Oriental Medicine (DAOM); California-licensed primary care provider specializing in women's health and aging; nationally board-certified through NCCAOM.
Areas available for expert commentary
- perimenopause and menopause
- female sexual health
- DHEA and androgen biology
- genital hormone signaling
- dyspareunia and sexual discomfort
- genitourinary health
- postpartum genital and urinary health
- osteoporosis and bone health
- healthy aging in women
- precision and personalized medicine
- metabolomic approaches to midlife women's health
- independent scientific research and the Ronin model
For journalists, editors, and podcast hosts
Laura is available for expert-source interviews, podcast conversations, journalist commentary, contributed articles, scientific background discussions, and panels.
She is particularly interested in conversations that go beyond generic menopause advice and examine where established biology, clinical convention, and unanswered research questions do not yet align.
Media inquiries: laura@drlaurakelly.com — subject line "Media." Response within 24 hours, Monday–Friday, Pacific time.
Media bio
Laura Kelly, DAOM is a researcher, author, and clinician studying several overlooked problems in women's health: why established androgen biology has not been translated into a standard treatment framework for the external vulva; the vulva as a distinct treatment target; route of local hormone delivery; and the separation of sexual drive from genital capacity across midlife. She is a Research Scholar at the Ronin Institute and US Principal Investigator on a 26-country comparative study of menopause led from the University of Bern. She is a California-licensed primary care provider specializing in women's health and aging, and a member of the Endocrine Society and the International Society for the Study of Women's Sexual Health. Her Drive–Capacity Model of midlife female sexual function was published by Oxford Academic in 2026.
One-line bio
Laura Kelly, DAOM is a researcher studying vulvar hormone biology, female sexual function, and overlooked treatment gaps across perimenopause and menopause.
Disclosure
Laura Kelly is the founder and Chief Scientist of The Vulva Company, which develops external vulvar-care products, including a liposomal DHEA formulation.
Her scientific and educational work includes subjects relevant to the company's area of activity: vulvar biology, DHEA, sex-steroid signaling, hormone delivery routes, and female sexual function.
Commercial affiliations are disclosed in scientific publications, interviews, and professional commentary.
ORCID: 0000-0001-6586-7308